Innovative Treatment Approach Zenflow's Spring System offers a minimally invasive solution for urinary obstruction caused by BPH, providing a compelling alternative to traditional surgery. This positions the company as a key player in solving clinical challenges with innovative device technology.

Strong Funding Momentum With a total funding of $55 million across multiple Series rounds including a recent $24 million Series C, Zenflow has demonstrated substantial investor confidence, supporting expansion, clinical trials, and market penetration efforts.

Clinical Validation Ongoing clinical trials showing positive results up to four years after treatment enhance the credibility of Zenflow’s solution, creating opportunities to engage healthcare providers eager for proven minimally invasive BPH treatments.

Market Focus Operating within the medical equipment manufacturing industry in the US, specifically targeting urology, Zenflow has a strategic opportunity to expand within a specialized niche underserved by existing large players.

Growth Potential Given the company's relatively small size with 11 to 50 employees and revenue between 1M to 10M, there is significant room for growth, making Zenflow an attractive prospect for device distributors, hospitals, and health systems looking to innovate or expand minimally invasive urology options.